Publications by authors named "R Ratei"
Acute Lymphoblastic Leukemia (ALL) is the most frequent hematologic malignancy in children and adolescents. A strong prognostic factor in ALL is given by the Minimal Residual Disease (MRD), which is a measure for the number of leukemic cells persistent in a patient. Manual MRD assessment from Multiparameter Flow Cytometry (FCM) data after treatment is time-consuming and subjective.
View Article and Find Full Text PDFAn Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.
Cancers (Basel)
December 2021
Article Synopsis
- - Monitoring minimal residual disease (MRD) through flow cytometry (FCM) is essential for predicting outcomes in acute lymphoblastic leukemia (ALL), but requires skilled laboratory personnel and ongoing quality checks.
- - The international Berlin-Frankfurt-Münster (I-BFM) consortium created a comprehensive training and quality control program to standardize FCM-MRD practices across multiple reference labs.
- - Key elements of this program include a twinning maturation program, mandatory external quality assessments, regular data trials, and independent survey evaluations, resulting in significantly improved accuracy and consistency in MRD detection in pediatric ALL patients.
Minimal residual disease (MRD) as measured by multiparameter flow cytometry (FCM) is an independent and strong prognostic factor in B-cell acute lymphoblastic leukemia (B-ALL). However, reliable flow cytometric detection of MRD strongly depends on operator skills and expert knowledge. Hence, an objective, automated tool for reliable FCM-MRD quantification, able to overcome the technical diversity and analytical subjectivity, would be most helpful.
View Article and Find Full Text PDF